The developed healthcare systems in the German-speaking countries force manufacturers to produce evidence that demonstrates the (added) value of their innovative technology. Manufacturers are more and more obliged to supply data on patient benefit and, increasingly, health economic information.

Our job is to advise our clients as to what kind of information they should have available, when and for whom. Once the strategy and the time frame are agreed, we help our clients hands-on in creating the required value as soon and as cost-effectively as possible. We offer flexible and on-going services, including: 

Services: Value Dossier

In order to prepare for the reimbursement and market requirements it is often advisable to develop a generic Value Dossier, which can be customized to meet the needs of different target groups. The dossier may cover different sections such as:

• General information about the product / therapy
• Clinical evidence information
• Health economic information
• Value proposition

Services: Business Case / Profitability Analysis

We support our clients to develop a business case that demonstrates outcomes and cost-effectiveness of their novel technology. It is vital to choose an appropriate perspective that typically may be either a hospital/doctor or a payer/society view. This type of health economic data can be considered a solid basis for reimbursement and marketing activities and could be a very convincing argument for a quick introduction into the respective healthcare market.

Services: Availability of Evidence Analysis, Searches and Reviews

As an opportunity to speed up the introduction of new procedures into the reimbursement system, we offer to assess the quality of the available information and data with respect to benefit, medical necessity and economic rationale of your devices and procedures. Some of the services we offer include:

• Gap analysis and evidence development strategy, as an aid in determining how to build a case with objective evidence and where appropriate data is lacking (critique of existing or input into new study designs)
• Internal HTA / benefit assessment that identifies what the relevant authorities such as the IQWiG or the G-BA in Germany would expect to see at the point when they would undertake a full, systematic review
• “Quick” literature scans assessing and identifying key items of the evidence base for the device / technology under scrutiny
• Systematic literature search and review of the published evidence on a technology

Review and grading both the quantity and quality of the available studies according to the accepted scientific methodologies (e.g., G-BA & IQWiG)